Mr. Jeff Zygouras reports

NEUPATH HEALTH ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AS PART OF PLANNED TRANSITION, PRE-ANNOUNCES STRONG 2025 RESULTS

Neupath Health Inc. has released the timing and details for a planned leadership transition in 2026, as well as preliminary revenue and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) expectations for 2025. As part of its long-term succession planning, Neupath's president, Stephen Lemieux, will succeed Joseph Walewicz as chief executive officer effective April 1, 2026. Mr. Walewicz will continue his role on the board of directors and work closely with Neupath's leadership team to support Neupath's growth initiatives. The company also announced the promotion of Sandee Dela Cruz to the new position of chief information officer effective Jan. 1, 2026.

Mr. Lemieux returned to Neupath as president in May, 2025, and brings more than 20 years of experience in finance and operations, including multiple chief financial officer roles and an interim CEO role in public companies in the health care sector. Mr. Lemieux's experience includes work on many acquisition and licensing transactions, including Neupath's successful acquisition of HealthPointe in 2021, which catalyzed Neupath's Western Canada expansion.

Mr. Dela Cruz joined Neupath in 2024 as vice-president of information technology, and brings more than 20 years of experience driving technology innovation and business transformation, and has successfully led major initiatives, including M&As (mergers and acquisitions), enterprise implementations and automation projects. Mr. Dela Cruz was recognized as a Top 10 Mid-Market Chief Information Officer by Info-Tech in 2015, 2020 and 2023, ranking him amongst Canada's top IT leaders.

"I am honoured to become Neupath's next CEO. I am familiar with our team, the complexity of our business and the opportunities to continue growing Neupath, which will enable a smooth transition of responsibilities from Joe. I look forward to working with our talented and passionate team, as we continue to grow our business," said Mr. Lemieux. "As demonstrated by our preliminary 2025 results, the company continues to perform well heading into 2026. I want to congratulate Sandee on his well-deserved promotion, and thank Joe for his leadership and ongoing guidance."

"The board and I would like to thank Joe for his leadership over the past three and a half years and for leading an extensive program of corporate and operational improvements. These efforts addressed key corporate challenges and established a strong foundation for Neupath, enabling the organization to better serve patients while continuing to grow the business," said Jolyon Burton, director, key Neupath shareholder and co-founder of Bloom Burton & Co. "Importantly, Joe will remain closely involved with Neupath as a board member, a significant shareholder and in a consulting capacity, providing continuity and ongoing strategic guidance to the leadership team. With Stephen as CEO, Jeff Zygouras as CFO and Sandee as CIO, we are confident in the continued success and execution of Neupath's significant growth strategy."

Preliminary 2025 results

Neupath expects to report audited 2025 results on March 26, 2026. Preliminary numbers for fiscal 2025 demonstrate a continuing trend in Neupath's results:

• Total revenue is expected to be in the range of $86-million and $88-million for the year, versus $72.8-million for 2024.
• Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) is expected to be between $5.6-million to $6.0-million for the year, versus $3.8-million for 2024.

About Neupath Health Inc.

Neupath operates a network of health care clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centred multidisciplinary care. The company operates a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports-related injuries and concussions. In addition, Neupath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of health care providers, as well as contract research services to pharmaceutical and biotechnology companies. Neupath is focused on enabling each individual to live their best life.

We seek Safe Harbor.